Domperidone: A Peripherally Acting Dopamine2-Receptor Antagonist

@inproceedings{Barone1999DomperidoneAP,
  title={Domperidone: A Peripherally Acting Dopamine2-Receptor Antagonist},
  author={Joseph A. Barone},
  booktitle={The Annals of pharmacotherapy},
  year={1999}
}
  • J. Barone
  • Published in The Annals of pharmacotherapy 1 April 1999
  • Medicine, Psychology
OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of domperidone in the treatment of gastrointestinal motility disorders and emesis. DATA SOURCES: MEDLINE and Excerpta Medica online databases were searched to identify published reports. STUDY SELECTION: Domperidone has been marketed worldwide outside the US since 1978, and extensive clinical data for this drug are available. This review focuses on the clinical experience from controlled studies of domperidone in the… 

Tables from this paper

Cardiac safety concerns for domperidone, an antiemetic and prokinetic, and galactogogue medicine
TLDR
It is possible that domperidone may be used as a galactogogue without direct risk to healthy breast feeding women, but more safety information should be sought in this situation.
Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine.
TLDR
The lack of pharmacokinetic interactions indicates that a dose adjustment of rotigotine transdermal patch is not necessary with concomitant use of domperidone, and this study shows no evidence for an interaction of dom peridone on bioavailability and steady-state pharmacokinetics of transdermally applied non-ergolinic dopamine agonist Rotigotine.
Domperidone withdrawal in a breastfeeding woman
TLDR
A case of domperidone withdrawal in a nursing woman, along with a tapering schedule that appears to decrease the likelihood of withdrawal symptoms is reported, hoping this case will shed light on the importance of tapering domPeridone as well as provide a description of the symptoms of dom peridone withdrawals in this population.
Domperidone for Hypotension in Parkinson's Disease: A Systematic Review.
TLDR
Domperidone may help to ameliorate OH associated with dopaminergic medications in PD, namely when used in conjunction with apomorphine.
Domperidone as an unintended antipsychotic
  • Jack Ferrier
  • Medicine
    Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC
  • 2014
TLDR
It is seen that domperidone between 30 and 160 mg/d could function as an antipsychotic, and it seems plausible that dom peridone could produce the same adverse effects as intended antipsychotics, which have many side effects and poorly understood withdrawal effects.
Domperidone safety: a mini-review of the science of QT prolongation and clinical implications of recent global regulatory recommendations.
TLDR
A review of the risk of QT prolongation and cardiac adverse effects with domperidone finds limited case reports supporting an association with cardiac dysfunction, and the frequently cited case-control studies have significant flaws.
Domperidone in Parkinson's disease: a perilous arrhythmogenic or the gold standard?
TLDR
Despite domperidone being recognized as the first choice for treating gastrointestinal symptoms PD, doses above 30 mg/daily should only be considered with special caution taking into account its potential cardiotoxic effects.
Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D2/D3 Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor
TLDR
The results indicate that TAK‑906 is relatively insensitive to inhibition of cytochrome P450 3A4, and cardiovascular safety concerns associated with domperidone are unlikely to be elicited by trazpiroben under similar conditions.
Domperidone Should Not Be Considered a No-Risk Alternative to Cisapride in the Treatment of Gastrointestinal Motility Disorders
TLDR
Domperidone possesses cardiac electrophysiological effects similar to those of cisapride and class III antiarrhythmic drugs, and should not be considered a no-risk alternative to cisAPride, a drug that was recently withdrawn from the US market.
Clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics
TLDR
It has been suggested that the serotonergic (5‐HT4) component of some antidopaminergic prokinetics may enhance their therapeutic efficacy in gastrointestinal disorders, such as functional dyspepsia and diabetic gastroparesis.
...
...

References

SHOWING 1-10 OF 161 REFERENCES
Use of metoclopramide, domperidone, and cisapride in the management of diabetic gastroparesis.
TLDR
Although metoclopramide is currently the first-line agent for the management of gastroparesis, domperidone and cisapride both possess properties that may make them useful alternatives in patients who are unresponsive to or cannot tolerate metoclobramide therapy.
Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic.
TLDR
Alleviation of the dose-limiting peripheral side effects of the anti-Parkinsonian drugs bromocriptine and levodopa, enables a higher optimum dose, with consequent improvement in Parkinsonian symptoms.
Metoclopramide: pharmacology and clinical application.
TLDR
Metoclopramide's effect on the medullary chemoreceptor trigger zone makes it useful as a routine anti-emetic and in preventing vomiting induced by antineoplastic drugs, particularly cisplatin.
Domperidone: an alternative to metoclopramide
  • Medicine
    Drug and therapeutics bulletin
  • 1988
TLDR
The anti-emetic drug domperidone (Motilium - Janssen) was introduced in 1982 and continues to be promoted, especially since the arrival of a second brand (Evoxin - Sterling).
Domperidone, a new dopamine antagonist.
TLDR
Domperidone has been approved for use in Canada for the symptomatic management of upper gastrointestinal tract motility disorders and to prevent gastrointestinal symptoms associated with the use of dopamine agonist agents in Parkinson's disease.
Pharmacokinetics and Dose Proportionality of Domperidone in Healthy Volunteers
TLDR
The area under the plasma concentration‐time curve (AUC) data demonstrated bioequivalence of base and maleate tablets and Dose proportionality of domperidone was studied in 12 subjects at solution doses of 10, 20, and 40 mg, indicating linear pharmacokinetics of dom peridone over the dose range studied.
Domperidone, metoclopramide, and placebo. All give symptomatic improvement in gastroesophageal reflux.
TLDR
It is concluded that a significant placebo effect is present in the treatment of gastroesophageal reflux and no significant difference was demonstrated in symptomatic improvement between placebo, domperidone, and metoclopramide in this study.
Effect of domperidone on gastro-oesophageal function in normal human subjects.
TLDR
In conclusion, domperidone given orally in a dose that has been shown to accelerate gastric emptying does not influence gastro-oesophageal sphincter pressure or peristaltic activity in the normal oesophagus.
Prokinetic agents for lower gastrointestinal motility disorders
TLDR
Cisapride appears to hold the most promise for patients with colonie motility disorders, and in patients with postoperative ileus, cisapride is associated with an increased return of bowel function compared with placebo.
Effects of intravenous and oral domperidone on the motor function of the stomach and small intestine.
TLDR
The results suggest that domperidone improves motor function in the proximal part of the gastrointestinal tract and synchronizes motor function due to its protracted activity.
...
...